These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Author: Lopes SR, Martins C, Teixeira M, Tomás D.
    Journal: World J Gastroenterol; 2024 Sep 14; 30(34):3929-3931. PubMed ID: 39350781.
    Abstract:
    Tofacitinib is an oral small-molecule Janus kinase (JAK) inhibitor that preferentially inhibits JAK1 and JAK3. Its efficacy in inducing and maintaining remission in ulcerative colitis (UC) as well as its safety profile has been demonstrated in multicenter, randomized, double-blind, placebo-controlled trials. Additionally, real-world studies evaluating the effectiveness and adverse effects of tofacitinib have been conducted, affirming its clinical efficacy in moderate-to-severe UC.
    [Abstract] [Full Text] [Related] [New Search]